Included in the formulation
АТХ:G.03 Sex hormones and modulators of the reproductive system
Pharmacodynamics:Modulates the effects of estrogens.
Stimulates the secretory phase in myometrium, creates conditions for the development of a fertilized egg (contributes to the preservation of pregnancy); has tocolytic effect - reduces the sensitivity of the myometrium to oxytocin.
Stimulation of the development of mammary glands.
Stimulates the secretory activity of trophoblasts and the production of aldosterone adrenal glands.
It binds to cytosolic receptors, initiates transcription and increases protein synthesis. Reduces the stability of the hormone-receptor complex, turns off hormone-sensitive genes through direct interaction with the nuclear progestin receptor. Increases the number of progestin receptors and increases the production of progesterone by triggering the negative feedback mechanism of inhibition of estrogen receptors.
Pharmacokinetics:Has a high absorption. Biotransformatsya in the liver. Eliminated by the kidneys (in the form of metabolites).
Indications:Threatening miscarriage, habitual miscarriage, threat of premature birth.
XV.O20-O29.O20.0 Threatening abortion
XIV.N80-N98.N96 Habitual miscarriage
Contraindications:Hypersensitivity, hepatic insufficiency, Johnson's syndrome, Rotor syndrome, thrombophlebitis,thromboembolic complications, cerebrovascular accident, tumors of the dairy and sex glands, toxicosis of pregnancy (in the anamnesis), herpes (including in the anamnesis), breast-feeding.
Application in children: eEffective and safety have not been studied.
Carefully:Inflammatory diseases of the kidneys, CHF, decreased tolerance to glucose.
Pregnancy and lactation:The category of FDA recommendations is not defined (progesterone - FDA recommendation category D). Progestins penetrate the placenta, may cause developmental disorders of the fetus: hypospadias in the male fetus, virilization of the external genital organs in the fetus of the female.
There is no information on the penetration into breast milk. Not recommended. Progestins penetrate into breast milk. The effect of many progestins on newborns is not known.
Dosing and Administration:Habitual miscarriage - 5 mg 2 times a day for 1 month or more after the critical period, then the dose can be reduced and 15 days before delivery stop taking.
Threatening miscarriage - 5 mg 3 times a day (but not more than 20 mg) for 5-7 days, until the symptoms disappear.
Premature birth (threat) - the dose and duration of treatment in each case is determined individually (oral intake).
Side effects:From the digestive system: symptoms of dyspepsia, nausea, cholestatic jaundice.
From the side of the central nervous system: headache, depression, insomnia, drowsiness.
From the urinary system: fluid retention, edematous syndrome.
From the endocrine system: weight gain, galactorrhea, swelling of the mammary glands, and a decrease in glucose tolerance.
Other: thrombophlebitis, thromboembolism, hyperthermia, acne.
Overdose:There is no specific antidote. Treatment is symptomatic.
Interaction:Inducers of microsomal oxidation reduce the effectiveness of allylastrenol, inhibitors of microsomal liver enzymes increase the risk of side effects.
Special instructions:Reduces the feeling of heat ("hot flashes") in postmenopause (at a dose of 30 mg / day, then - a dose reduction for 15 days to 5 mg / day), but the effect of another synthetic progestin - linestrenol (10 mg / day, then - decrease doses up to 1.25 mg / day) begins after the second week of use, and allylestrenol - after 6 weeks.
Patients with diabetes mellitus
regular monitoring of glycemic parameters is required.
It is not represented in the United States Pharmacopeia.